BACKGROUND: Echinacea has been widely used as an herbal remedy for the common cold, but efficacy studies have produced conflicting results, and there are a variety of echinacea products on the market with different phytochemical compositions. We evaluated the effect of chemically defined extracts from Echinacea angustifolia roots on rhinovirus infection. METHODS: Three preparations of echinacea, with distinct phytochemical profiles, were produced by extraction from E. angustifolia roots with supercritical carbon dioxide, 60 percent ethanol, or 20 percent ethanol. A total of 437 volunteers were randomly assigned to receive either prophylaxis (beginning seven days before the virus challenge) or treatment (beginning at the time of the challenge) either with one of these preparations or with placebo. The results for 399 volunteers who were challenged with rhinovirus type 39 and observed in a sequestered setting for five days were included in the data analysis. RESULTS: There were no statistically significant effects of the three echinacea extracts on rates of infection or severity of symptoms. Similarly, there were no significant effects of treatment on the volume of nasal secretions, on polymorphonuclear leukocyte or interleukin-8 concentrations in nasal-lavage specimens, or on quantitative-virus titer. CONCLUSIONS: The results of this study indicate that extracts of E. angustifolia root, either alone or in combination, do not have clinically significant effects on infection with a rhinovirus or on the clinical illness that results from it. Copyright 2005 Massachusetts Medical Society.
RCT Entities:
BACKGROUND:Echinacea has been widely used as an herbal remedy for the common cold, but efficacy studies have produced conflicting results, and there are a variety of echinacea products on the market with different phytochemical compositions. We evaluated the effect of chemically defined extracts from Echinacea angustifolia roots on rhinovirus infection. METHODS: Three preparations of echinacea, with distinct phytochemical profiles, were produced by extraction from E. angustifolia roots with supercritical carbon dioxide, 60 percent ethanol, or 20 percent ethanol. A total of 437 volunteers were randomly assigned to receive either prophylaxis (beginning seven days before the virus challenge) or treatment (beginning at the time of the challenge) either with one of these preparations or with placebo. The results for 399 volunteers who were challenged with rhinovirus type 39 and observed in a sequestered setting for five days were included in the data analysis. RESULTS: There were no statistically significant effects of the three echinacea extracts on rates of infection or severity of symptoms. Similarly, there were no significant effects of treatment on the volume of nasal secretions, on polymorphonuclear leukocyte or interleukin-8 concentrations in nasal-lavage specimens, or on quantitative-virus titer. CONCLUSIONS: The results of this study indicate that extracts of E. angustifolia root, either alone or in combination, do not have clinically significant effects on infection with a rhinovirus or on the clinical illness that results from it. Copyright 2005 Massachusetts Medical Society.
Authors: Kelly A Shipkowski; Joseph M Betz; Linda S Birnbaum; John R Bucher; Paul M Coates; D Craig Hopp; Duffy MacKay; Hellen Oketch-Rabah; Nigel J Walker; Cara Welch; Cynthia V Rider Journal: Food Chem Toxicol Date: 2018-04-04 Impact factor: 6.023
Authors: Fabiana N Fonseca; Genovefa Papanicolaou; Hong Lin; Clara B S Lau; Edward J Kennelly; Barrie R Cassileth; Susanna Cunningham-Rundles Journal: Int Immunopharmacol Date: 2014-01-13 Impact factor: 4.932
Authors: Marlies Karsch-Völk; Bruce Barrett; David Kiefer; Rudolf Bauer; Karin Ardjomand-Woelkart; Klaus Linde Journal: Cochrane Database Syst Rev Date: 2014-02-20
Authors: Jeannette Lee; Gerald Andriole; Andrew Avins; E David Crawford; Harris Foster; Steven Kaplan; Karl Kreder; John Kusek; Andrew McCullough; Kevin McVary; Sreelatha Meleth; Michael Naslund; J Curtis Nickel; Leroy Nyberg; Claus Roehrborn; O Dale Williams; Michael Barry Journal: Clin Trials Date: 2009-12-09 Impact factor: 2.486